# A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

> **NCT03404115** · PHASE2 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 300 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** Reproxalap Ophthalmic Solution (0.25%)
- **DRUG:** Reproxalap Ophthalmic Solution (0.1%)
- **DRUG:** Vehicle Ophthalmic Solution

## Key facts

- **NCT ID:** NCT03404115
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-02
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-07-11
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03404115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03404115, "A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03404115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*